Local drug delivery in recurrent malignant gliomas

A. Boiardi, M. Eoli, A. Salmaggi, E. Lamperti, A. Botturi, A. Solari, F. Di Meco, G. Broggi, A. Silvani

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.

Original languageEnglish
JournalNeurological Sciences
Volume26
Issue numberSUPPL. 1
DOIs
Publication statusPublished - May 2005

Fingerprint

Glioma
Nimustine
Mitoxantrone
Pharmaceutical Preparations
temozolomide
Disease-Free Survival
Convection
Survival
Selection Bias
Liposomes
Histology
Appointments and Schedules
Drug Therapy
Therapeutics

Keywords

  • Doxorubicine
  • Glioblastoma
  • Loco-regional chemotherapy
  • Nimustine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Local drug delivery in recurrent malignant gliomas. / Boiardi, A.; Eoli, M.; Salmaggi, A.; Lamperti, E.; Botturi, A.; Solari, A.; Di Meco, F.; Broggi, G.; Silvani, A.

In: Neurological Sciences, Vol. 26, No. SUPPL. 1, 05.2005.

Research output: Contribution to journalArticle

@article{b9052070d40641bdaa94d41a32e61caa,
title = "Local drug delivery in recurrent malignant gliomas",
abstract = "In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.",
keywords = "Doxorubicine, Glioblastoma, Loco-regional chemotherapy, Nimustine",
author = "A. Boiardi and M. Eoli and A. Salmaggi and E. Lamperti and A. Botturi and A. Solari and {Di Meco}, F. and G. Broggi and A. Silvani",
year = "2005",
month = "5",
doi = "10.1007/s10072-005-0403-z",
language = "English",
volume = "26",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Local drug delivery in recurrent malignant gliomas

AU - Boiardi, A.

AU - Eoli, M.

AU - Salmaggi, A.

AU - Lamperti, E.

AU - Botturi, A.

AU - Solari, A.

AU - Di Meco, F.

AU - Broggi, G.

AU - Silvani, A.

PY - 2005/5

Y1 - 2005/5

N2 - In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.

AB - In recurrent malignant gliomas, we scheduled a protocol by adding to systemic temozolomide a local treatment delivered through a reservoire positioned in the surgically created cavity, consisting of either mitoxantrone, liposome-loaded doxorubicine or nimustine (ACNU). The progression-free survival (PFS) and survival time (ST) of the whole group of 112 patients were 8.3 and 11 months, respectively, in GBM patients, and 14 and 18 months in AA patients. To limit the selection bias in recruitment we matched locally treated patients with the whole group of patients treated for 3 years and having undergone the same protocol with the exception of local drug delivery. Variables such as age, histology and local chemotherapy delivery were proved to be statistically significant independent factors on adjunctive PFS and ST. Another group of 12 recurrent malignant gliomas with further progression was locally managed according to convection-enhanced delivery (CED) of mitoxantrone; the preliminary results show good tolerability of the schedule.

KW - Doxorubicine

KW - Glioblastoma

KW - Loco-regional chemotherapy

KW - Nimustine

UR - http://www.scopus.com/inward/record.url?scp=18344367863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344367863&partnerID=8YFLogxK

U2 - 10.1007/s10072-005-0403-z

DO - 10.1007/s10072-005-0403-z

M3 - Article

C2 - 15883691

AN - SCOPUS:18344367863

VL - 26

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 1

ER -